Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.1.9
Consolidated Statements of Cash Flows (USD $)
12 Months Ended
Nov. 30, 2014
Nov. 30, 2013
Statement of Cash Flows [Abstract]    
Net income $ 553,623us-gaap_NetIncomeLoss $ 27,436us-gaap_NetIncomeLoss
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization expense 377,008ccel_DepreciationAndAmortizationExpense 394,502ccel_DepreciationAndAmortizationExpense
Abandonment of patents 25,649us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill 378,837us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Loss on sale of property and equipment   44,428us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Compensatory element of stock options 404,233us-gaap_ShareBasedCompensation 271,961us-gaap_ShareBasedCompensation
Provision for doubtful accounts 1,303,436us-gaap_ProvisionForDoubtfulAccounts 816,464us-gaap_ProvisionForDoubtfulAccounts
Equity in losses of affiliate 362,884us-gaap_IncomeLossFromEquityMethodInvestments 154,051us-gaap_IncomeLossFromEquityMethodInvestments
Changes in assets and liabilities:    
Accounts receivable (2,038,973)us-gaap_IncreaseDecreaseInAccountsReceivable (1,316,135)us-gaap_IncreaseDecreaseInAccountsReceivable
Notes receivable 550,782us-gaap_IncreaseDecreaseInNotesReceivables 564,723us-gaap_IncreaseDecreaseInNotesReceivables
Prepaid expenses (220,769)us-gaap_IncreaseDecreaseInPrepaidExpense (39,071)us-gaap_IncreaseDecreaseInPrepaidExpense
Other current assets 31,858us-gaap_IncreaseDecreaseInOtherCurrentAssets 53,281us-gaap_IncreaseDecreaseInOtherCurrentAssets
Deposits and other assets, net 37,628ccel_IncreaseDecreaseInDepositsAndOtherAssets 31,140ccel_IncreaseDecreaseInDepositsAndOtherAssets
Accounts payable (201,915)us-gaap_IncreaseDecreaseInAccountsPayable (15,148)us-gaap_IncreaseDecreaseInAccountsPayable
Accrued expenses (329,112)us-gaap_IncreaseDecreaseInAccruedLiabilities (1,116,947)us-gaap_IncreaseDecreaseInAccruedLiabilities
Deferred revenue 698,489us-gaap_IncreaseDecreaseInDeferredRevenue 572,458us-gaap_IncreaseDecreaseInDeferredRevenue
Net cash provided by operating activities 1,554,821us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 821,980us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities:    
Release of restricted cash held in escrow 763,989us-gaap_IncreaseDecreaseInRestrictedCash 1,608,714us-gaap_IncreaseDecreaseInRestrictedCash
Purchases of property and equipment (120,517)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (349,784)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Purchases of marketable securities and other investments, net (64,764)us-gaap_PaymentsForProceedsFromInvestments (24,250)us-gaap_PaymentsForProceedsFromInvestments
Investments in patents   (47,525)us-gaap_PaymentsToAcquireIntangibleAssets
Investment in affiliate (187,500)us-gaap_PaymentsToAcquireEquityMethodInvestments (37,693)us-gaap_PaymentsToAcquireEquityMethodInvestments
Net cash provided by investing activities 391,208us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations 1,149,462us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:    
Treasury stock purchases (2,671,060)us-gaap_PaymentsForRepurchaseOfCommonStock (738,618)us-gaap_PaymentsForRepurchaseOfCommonStock
Proceeds from the exercise of stock options 79,142us-gaap_ProceedsFromStockOptionsExercised 14,950us-gaap_ProceedsFromStockOptionsExercised
Net cash used in financing activities (2,591,918)us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations (723,668)us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
(Decrease) increase in cash and cash equivalents (645,889)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 1,247,774us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents - beginning of period 3,925,156us-gaap_CashAndCashEquivalentsAtCarryingValue 2,677,382us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents - end of period 3,279,267us-gaap_CashAndCashEquivalentsAtCarryingValue 3,925,156us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental non-cash disclosure:    
Disposition of Cryo-Cell common stock held by Saneron, increase in investment $ 81,480us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1